Abstract
In this letter, we wish to point out the possibility of transformation of myelofibrosis in acute lymphocytic leukemia without the presence of JAK2V617F mutation. Myeloproliferative neoplasms (MPN) are hematologic malignant diseases characterized by a clonal proliferation of one or several lineages [1]. They represent a phenotypically diverse group of chronic myeloid malignancies that are characterized by the presence of clonal hematopoiesis and an excessive production of terminally differentiated myeloid blood cells. Typically, they include four main clinical entities: polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myeloid leukemia (CML). PV, ET, and PMF are usually subcategorized as bcr-abl-negative MPN. However, sporadic cases of bcr-abl-positive patients with transformation of primary myelofibrosis were reported but without JAK2V617F mutation [2]. The prevalence of JAK2V617F mutation [3] differs between various variants of MF with the higher detection rate for patients with post-PV MF (91 %) if compared to PMF (45 %) and post-ET MF (39 %). Some works emphasize the importance of the predictive role of JAK2V617F mutation for this transformation. JAK2V617F
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call